Interim report January - June 2007

Interim report January - June 2007

•  Net sales in the second quarter amounted to 131.1 MSEK (128.3) and to 250.0
MSEK (249.0) in the period January - June. At comparable exchange rates and
excluding the Chem Dev product area which is being closed down sales increased
by 8% in both periods.

•  The operating result for the second quarter amounted to 11.1 MSEK (-2.2). The
operating result for the first six months 2007 amounted to 18.3 MSEK (-14.3).

•  Profit after tax for the second quarter amounted to 38.1 MSEK (4.0) and
earnings per share to 0.43 SEK (0.04).

•  In the second quarter capitalization of deferred income taxes recoverable was
made to the amount of 27.6 MSEK.

•  For the period January - June 2007 net profit amounted to 45.3 MSEK (-16.8)
and earnings per share to 0.51 SEK (-0.19).

•  Biotage has signed an agreement with one of China's leading contract research
companies, Shanghai Chempartner Co., Ltd. concerning the delivery of
instruments. The order has a value of approx. 10 million SEK, making this
Biotage's single largest order from China to date.

•  A new market segment, Molecular Imaging, was introduced.




For further information, please contact:
Torben Jörgensen, president and CEO, phone: +46 707 49 05 84	
Mats-Olof Wallin, CFO, phone: +46 705 93 52 73

About Biotage
Biotage is a global company active in life science research with strong
technologies, a broad range of operations and a long-term view of the market.
The company offers solutions, knowledge and experience in the areas of genetic
analysis and medicinal chemistry. In 2005 business and products from the company
Argonaut were acquired, further strengthening the product range in medicinal
chemistry. The customers include the world's top 30 pharma companies, the
world's top 20 biotech companies, and leading academic institutes. The company
is headquartered in Uppsala and has subsidiaries in the U.S., Japan, UK, Germany
and several other European countries. Biotage has 332 employees and had sales of
520 MSEK in 2006. Biotage is listed on the Stockholm stock exchange. Website:
www.biotage.com